The Measurement
Challenge
Why standard laboratory instruments fall short in EV detection.
Extracellular vesicles (EVs) are subcellular in size and therefore are too small to be detected with routine laboratory instruments.
In blood, EVs are vastly outnumbered by lipoproteins, further complicating their characterization
The Need for Standardization
These challenges contribute to variability in measurements across instruments and laboratories, ultimately hampering clinical implementation
For EVs to become reliable cardiovascular biomarkers, their identification and quantification require robust standardization, calibration, and clinical validation
We have overcome these barriers.
Beyond Diagnostics: Targeted Drug Delivery
Beyond their role as biomarkers, EVs show immense promise as therapeutic tools. We are exploring their use as vehicles for targeted drug delivery directly to the heart, positioning EV technology at the forefront of precision cardiovascular medicine
Cargo analysis provides information on the cells of origin and on disease development. The common presence of EVs in body fluids makes them clinically interesting, providing minimally invasive and novel biomarkers from easily accessible body fluids or “liquid biopsies”
Single EV cargo analysis will facilitate early disease detection, prognosis assessment, and monitoring of treatment response, positioning EVs as a promising tool in precision medicine
EVcount is currently operating under the umbrella of Amsterdam University Medical Center to assess business feasibility. The activities are conducted under the supervision of the technology transfer office.
